You just read:

Braeburn Pharmaceuticals Announces Commercialization Plans for Probuphine® (buprenorphine) Implant, Six-Month Treatment for Opioid Dependence

News provided by

Braeburn Pharmaceuticals

31 May, 2016, 16:30 ET